R cells: Involvement of lipid rafts and Bid. Arch Biochem Biophys
R cells: Involvement of lipid rafts and Bid. Arch Biochem Biophys 2008, 476:113-123. 4. Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood 2005, 106:LCZ696 biological activity 1154-1163. 5. Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O’Brien S, Radich J, Scher NS, Smith FO, Stone RM, Tallman MS: End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007, 109:1810-1816. 6. Lancet JE, Giralt S: Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Compr Canc Netw 2008, 6:1017-1025. 7. Kohrt HE, Coutre SE: Optimizing therapy for acute myeloid leukemia. J Natl Compr Canc Netw 2008, 6:1003-1016. 8. Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW: Comparison of imatinib mesylate, dasatinib (BMS354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108:2332-2338. 9. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Bradford S, Agarwal P, Gollerkeri A, Baccarani M: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109:3207-3213. 10. Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, Aprili F, Perona G: Estimated 6-year event-free survival of 55 in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 1998, 12:144-149. 11. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Fo?R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006, 107:473-479. 12. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L, for the AIEOP-BFM-FCM-MRD-Study Group: Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009, 23:528-534.Conclusion We provide here the first evidence that a-bisabolol is an effective pro-apoptotic agent in primary ALL cells at concentrations and durations that spare normal blood and bone marrow cells. It retains cytotoxic potential in both imatinib mesylate-resistant and -sensitive Ph + BALL. It is PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28250575 also active against primary AML cells at slightly higher concentrations. Our findings support abisabolol as a possible candidate for the treatment of acute leukemias and establish a basis for studies in animal models.Acknowledgements The authors thank mathematics professor Vincenza Tomasello for her criticism and advice on numerical analysis and appreciate that she is surely a firm believer in Plato’s “Let nobody ignorant of geometry enter here”. This work was supported by grants from the Venetian Institute of Oncology (IOV), Padua (Italy) and from Fondazione Cariverona, V.
